Eevia Health Plc enters negotiations for a significant sales contract for 2025 with an option to extend until 2027
Eevia Health Plc (”Eevia” or the “Company”) has entered negotiations with a European food manufacturer to manufacture a new plant extract (the “Product”) with the potential for significant contribution to the Company’s topline and profits in 2025. The manufacturing would start earliest in December 2024 and will require 20% to 40% of Eevia's annual production capacity for 2025, with an option to extend both annual volumes and the contract period till 2027. The parties expect to finalize negotiations by the end of Q1-2024.The customer is a listed and well-established medium-sized European